1. Healthcare

  2. •

    Biotechnology
Corium International, Inc.

Corium International, Inc.

CORI
Corium International, Inc.US flagNASDAQ
12.68
USD
- -
- -
Corium International, Inc.
CORI
(NASDAQ)

Recent

price

12.68

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
TTM
FRC
19.21
8.68
4.23
2.19
1.48
1.1
1.01
Revenue per Share
-2.44
-2.4
-0.99
-1.52
-1.65
-1.64
-1.57
Basic EPS, GAAP
-1.02
-1.53
-1.51
-1.2
-1.41
-1.39
-1.32
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-35.2
-15.96
-10.19
-6.99
-7.52
-7.4
-7.18
Book Value per Share
-50.61
-21.71
0.51
1.52
-0.19
0.31
0.48
Tangible Book Value per Share
2
6
10
19
22
29
36
Basic Weighted Avg Shares
43
50
42
41
33
32
36
Sales/Revenue/Turnover
-2.02
2.04
-23.94
-51.35
-87.54
-124.76
-125.31
Operating Margin (%)
2
2
1
1
1
1
1
Depreciation Expense
-5
-14
-10
-28
-37
-48
-57
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-12.7
-27.6
-23.36
-69.52
-111.14
-149.99
-155.21
Profit Margin (%)
11
9
37
72
40
41
77
Working Capital
53
61
39
50
51
39
70
LT Debt
-106
-119
12
35
3
16
25
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'18
Mar'18
Jun'18
ST Debt
26
- -
- -
LT Borrowings
26
69
70
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
36
36
Market Capitalization
312
400
289

Working Capital

FRC

•

in mil. unless spec.
Dec'18
Mar'18
Jun'18
Total Current Assets
54
101
89
Cash, Cash Equivalents & STI
45
94
83
Accounts Receivable, Net
5
4
4
Inventories
3
2
2
Total Current Liabilities
39
12
12
Payables & Accruals
12
12
11
ST Debt
26
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
95.55%
468.24%
Free Cash Flow
- -
94.94%
28.49%
Net Income, GAAP
- -
74.53%
30.22%
Sales/Revenue/Turnover
- -
-4.94%
-3.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
8
7
11
8
33
2017
7
7
8
9
32
2018
9
10
8
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.42
-0.47
-0.34
-0.42
-1.65
2017
-0.46
-0.42
-0.43
-0.36
-1.64
2018
-0.37
-0.5
-0.34
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
Oncternal Therapeutics, Inc. (ONCT)
Ehouse Global, Inc. (EHOS)
Genus plc (GENSF)
Newron Pharmaceuticals S.p.A. (0QOI.L)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)
XORTX Therapeutics Inc. (XRTX)
Business
Corium International, Inc. Corium International, Inc. (CORI), a commercial-stage biopharmaceutical company, develops, manufactures and commercializes central nervous system therapies leveraging proprietary transdermal and transmucosal delivery technologies including Corplex and MicroCor platforms; core products comprise AZSTARYS, a CNS stimulant for attention deficit hyperactivity disorder in patients ages six years and older, and ADLARITY, a once-weekly donepezil transdermal system for mild, moderate or severe Alzheimer's dementia. The company provides contract development and manufacturing organization services for transdermal systems and oral thin films to pharmaceutical partners such as Teva Pharmaceuticals USA, Inc. and Agile Therapeutics, Inc.; it targets clinicians, patients and caregivers in the neuroscience sector with operations primarily in the US and licensing agreements extending to territories including Asia via partnerships like the 2023 exclusive collaboration with Lotus Pharmaceutical for ADLARITY. Founded in 1995 and headquartered in Menlo Park, California, Corium International records recent strategic changes including FDA approvals and commercial launches of AZSTARYS and ADLARITY in recent years, a 2022 manufacturing business spin-out and acquisition by Gurnet Point Capital with a $100 million investment from Webster Equity Partners to fuel neuroscience expansion, and validation of Corplex technology through ADLARITY approval alongside a 2018 take-private transaction.